SCHEMBL10093258

SCHEMBL10093258

O=C(NS(=O)(=O)C1CC1)[C@H]1C[C@H]1C(F)F

nearest known ligand 0.31

Predicted protein targets (top 2)

geneUniProtsupporting neighboursconfidence
CA1 P00915 1/20 0.31
CA2 P00918 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2048363 1.00 CA1 (0.31) CA1CA2
SCHEMBL20629688 0.76 SCN9A (0.32)
SCHEMBL17188775 0.76 SCN9A (0.32)
SCHEMBL21086437 0.73
SCHEMBL23394545 0.72
SCHEMBL15828901 0.72 CA1 (0.31) CA1CA2
SCHEMBL13559993 0.71 SCN9A (0.31)
SCHEMBL1433015 0.71 SCN9A (0.31)
Hydrochloric Acid SCHEMBL2054323 0.70 SCN9A (0.30)
SCHEMBL8206048 0.70

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3825312-A1 INTERMEDIATES FOR PREPARING INHIBITORS OF HEPATITIS C VIRUS Gilead Pharmasset LLC (US) 2021-05-26 EP disclosed
EP-3159345-A1 INHIBITORS OF HEPATITIS C VIRUS Gilead Sciences, Inc. (US) 2017-04-26 EP disclosed
WO-2012024373-A1 COMPOUNDS FOR THE TREATMENT OF HEPATITIS C BRISTOL-MYERS SQUIBB COMPANY (US) 2012-02-23 WO disclosed